

Paolo Durigutto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9030308/publications.pdf>

Version: 2024-02-01

25
papers

1,767
citations

331538

21
h-index

580701

25
g-index

28
all docs

28
docs citations

28
times ranked

2454
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. <i>Biomedicines</i> , 2021, 9, 1003.	1.4	44
2	Complement Activation and Thrombin Generation by MBL Bound to \hat{I}^2 -Glycoprotein I. <i>Journal of Immunology</i> , 2020, 205, 1385-1392.	0.4	16
3	Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2019, 103, 102288.	3.0	33
4	New insight into antiphospholipid syndrome: antibodies to \hat{I}^2 glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , 2019, 104, 819-826.	1.7	40
5	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 433-440.	3.5	95
6	Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage. <i>Frontiers in Immunology</i> , 2017, 8, 1093.	2.2	20
7	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. <i>Blood</i> , 2016, 127, 365-367.	0.6	67
8	C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. <i>Nature Communications</i> , 2016, 7, 10346.	5.8	224
9	Critical Role and Therapeutic Control of the Lectin Pathway of Complement Activation in an Abortion-Prone Mouse Mating. <i>Journal of Immunology</i> , 2015, 195, 5602-5607.	0.4	30
10	Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. <i>Leukemia</i> , 2015, 29, 406-414.	3.3	64
11	A non- \hat{I}^2 complement-fixing antibody to \hat{I}^2 glycoprotein I as a novel therapy for antiphospholipid syndrome. <i>Blood</i> , 2014, 123, 3478-3487.	0.6	120
12	Orchestration of Inflammation and Adaptive Immunity in <i>Borrelia burgdorferi</i> -Induced Arthritis by Neutrophil-Activating Protein A. <i>Arthritis and Rheumatism</i> , 2013, 65, 1232-1242.	6.7	32
13	Prevention of Arthritis by Locally Synthesized Recombinant Antibody Neutralizing Complement Component C5. <i>PLoS ONE</i> , 2013, 8, e58696.	1.1	24
14	Control of arthritis by local synthesis of recombinant antibody neutralizing C5. <i>Immunobiology</i> , 2012, 217, 1160-1161.	0.8	0
15	Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. <i>Arthritis and Rheumatism</i> , 2012, 64, 2559-2567.	6.7	39
16	In vivo distribution of \hat{I}^2 glycoprotein I under various pathophysiologic conditions. <i>Blood</i> , 2011, 118, 4231-4238.	0.6	113
17	Innate immunity, through late complement components activation, contributes to the development of early vascular inflammation and morphologic alterations in experimental diabetes. <i>Atherosclerosis</i> , 2011, 216, 83-89.	0.4	11
18	Mannose-binding lectin is produced by vaginal epithelial cells and its level in the vaginal fluid is influenced by progesterone. <i>Molecular Immunology</i> , 2010, 48, 281-286.	1.0	38

#	ARTICLE	IF	CITATIONS
19	Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 1303-1310.e4.	1.5	94
20	Posttransplant Ischemia-Reperfusion Injury In Transplanted Heart Is Prevented By A Minibody to the Fifth Component of Complement. <i>Transplantation</i> , 2008, 86, 1445-1451.	0.5	24
21	The Neutrophil-Activating Protein of <i>Helicobacter pylori</i> Crosses Endothelia to Promote Neutrophil Adhesion In Vivo. <i>Journal of Immunology</i> , 2007, 178, 1312-1320.	0.4	87
22	Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. <i>Blood</i> , 2007, 110, 536-543.	0.6	121
23	Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. <i>Arthritis and Rheumatism</i> , 2007, 56, 1187-1197.	6.7	29
24	Thrombus formation induced by antibodies to β_2 -glycoprotein I is complement dependent and requires a priming factor. <i>Blood</i> , 2005, 106, 2340-2346.	0.6	324
25	Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. <i>Clinical and Experimental Immunology</i> , 2004, 135, 186-193.	1.1	62